Tumor progression is initiated by a process of clonal evolution where cancer evolve through repeated process of clonal expansion, clonal selection and genetic diversification with highly variable patterns of genetic diversity resulting in tumor progression. The importance of this process has been increasingly recognized over the past decade: tumor heterogeneity, the major cause of therapeutic resistance to antitumor agents, results from the genetic, epigenetic and micro environmental selective pressure that tumour cells undergo during cancer progression. Tumor progression is driven by mutations that confer growth advantages to different subpopulations of cancer cells. As a tumor grows, these subpopulations expand, accumulate new mutations, and are subjected to selective pressures from the environment, including anticancer interventions. This clonal evolution process can lead to the emergence of therapy-resistant tumors and poses a major challenge for cancer eradication efforts.
Evolutionary biology of cancer, tumour microenvironment, cancer stem cells, Cancer evolution and immune evasion, Cellular competition, cooperation and cancer, transmissible cancer, evolvability and adaptation, cooperation and conflict in multicellularity, mathematical models, Anti- tumour agents
Academicians, scientists and researchers in oncology, radiation oncologist, Ph.D. scholars, young researchers, radiologists, radiation oncologists, surgeons, pathologists, epidemiologists, pharmaceutical companies
Evolutionary Biology of cancer conference 2020| Oncology and cancer research conferences 2020| Cancer Research conferences 2020| Cancer Conferences | Oncology conferences | Cancer evolution | Evolution and Ecology of Cancer Conferences | Biological insight and cancer evolution conference 2020| Cancer Research conferences Europe | Cancer Conferences USA | Cancer conferences Netherlands | Cancer | Amsterdam |
Holiday Inn Express Amsterdam - Sloterdijk Station, Amsterdam, Netherlands